Agnes Guerci-Bresler

Agnes Guerci-Bresler

UNVERIFIED PROFILE

Are you Agnes Guerci-Bresler?   Register this Author

Register author
Agnes Guerci-Bresler

Agnes Guerci-Bresler

Publications by authors named "Agnes Guerci-Bresler"

Are you Agnes Guerci-Bresler?   Register this Author

52Publications

2445Reads

8Profile Views

Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.

Cancer Med 2019 06 30;8(6):3296-3304. Epub 2019 Apr 30.

B2PHI Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases, Inserm U1181, UVSQ, Paris Saclay Univ, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558491PMC
June 2019

[NK cells: a major role in the antitumoral immunomodulation in CML].

Med Sci (Paris) 2018 Jun-Jul;34(6-7):540-546. Epub 2018 Jul 31.

Inserm UMR 1160, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France - France intergroupe des leucémies myéloïdes chroniques (Fi-LMC), Institut Bergonié, 33000 Bordeaux, France - Service d'hématologie adulte, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France.

View Article

Download full-text PDF

Source
https://www.medecinesciences.org/10.1051/medsci/20183406013
Publisher Site
http://dx.doi.org/10.1051/medsci/20183406013DOI Listing
January 2019

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Leuk Res 2017 09 26;60:94-102. Epub 2017 Jul 26.

INSERM, U935, F-86000 Poitiers, France; Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France; NSERM U935, F-94807 Villejuif, France; Université Paris Sud, F-94270 Le Kremlin-Bicêtre, France; Hôpital Bicêtre, Service d'Hématologie Biologique, F-94270 Le Kremlin Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.07.007DOI Listing
September 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

J Clin Oncol 2017 May 28;35(14):1591-1597. Epub 2017 Mar 28.

Sophie Park, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Université Grenoble Alpes, Grenoble; Jean-François Hamel and Sylvain Thépot, CHU d'Angers; Sylvain Thépot, Université d'Angers, Institut National de la Santé et de la Recherche Médicale, Unité 1232, and LabEx IGO, Angers; Andrea Toma, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil; Rosa Sapena and Pierre Fenaux, CHU Saint Louis, AP-HP, Université Paris X; François Dreyfus, CHU Cochin, AP-HP, Université Paris V, Paris; Charikleia Kelaidi, CHU Avicenne, Avicenne; Odile Beyne-Rauzy, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Agnès Guerci-Bresler, CHU Nancy, Nancy; Dominique Bordessoule, CHU Dupuytren, Limoges; Pascale Cony-Makhoul, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy; Stéphane Cheze, CHU de Caen, Caen; Eric Wattel, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon; Christian Rose, Université Catholique de Lille, Lille; Norbert Vey, Institut Paoli-Calmettes Marseille, Marseille, France; Maria Diez Campelo, Hospital Universitario de Salamanca, Salamanca; Teresa Bernal, Hospital Central de Asturias, Oviedo; Fernando Ramos, Hospital de León, León; Marisa Calabuig, Hospital Clínico de Valencia; Guillermo F. Sanz, Hospital Universitario y Politecnico La Fe, Valencia, Spain; Valeria Santini and Alessandro Sanna, Azienda Ospedaliero Universitaria (AOU) Careggi and University of Florence, Florence; Enrico Balleari, Istituto di Ricovero e Cura a Carattere Scientifico AOU San Martino di Genova, Genova; Daniela Gioia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Dario Ferrero, Università degli Studi di Torino; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Torino; Giovanni Cametti, Ospedale Maggiore di Chieri, Chieri; Fabrizio Pane, Università Federico II, Napoli, Italy; Mikkael A. Sekeres and Jaime Fensterl, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Rami Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Gail J. Roboz, Weill Medical College of Cornell University, New York, NY; Jennifer Kaivers and Ulrich Germing, University of Düsseldorf, Düsseldorf; Katharina Götze and Catharina Müller-Thomas, Universität München, München, Germany; and Ioannis Kotsianidis, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3271DOI Listing
May 2017

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

J Clin Oncol 2017 Jan 31;35(3):298-305. Epub 2016 Oct 31.

Gabriel Etienne and François-Xavier Mahon, Institut Bergonié, Bordeaux; Joëlle Guilhot and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers; Delphine Rea, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP); Bruno Varet, Hôpital Necker, AP-HP et Université Paris Descartes, Paris; Françoise Rigal-Huguet, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse; Franck Nicolini, Centre Hospitalier Lyon Sud, Pierre Bénite; Aude Charbonnier, Institut Paoli Calmette, Marseille; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Laurence Legros, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice; Martine Gardembas, CHU d'Angers, Angers; Viviane Dubruille, CHU Hôtel-Dieu, Nantes; Michel Tulliez, Hôpital Henri Mondor, Créteil; Marie-Pierre Noel, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille; Jean-Christophe Ianotto, CHU Morvan, Brest; Bruno Villemagne, Centre Hospitalier Départemental La Roche-Sur-Yon, La Roche-Sur-Yon; Martin Carré, Hôpital Albert Michallon, CHU de Grenoble, Grenoble; Philippe Rousselot, Hôpital André Mignot, Le Chesnay; and François-Xavier Mahon, CHU de Bordeaux, INSERM U1218, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2914DOI Listing
January 2017

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J Clin Oncol 2014 Feb 9;32(5):424-30. Epub 2013 Dec 9.

Philippe Rousselot, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines, Versailles; Aude Charbonnier, Institut Paoli Calmette, Marseille; Pascale Cony-Makhoul, Hôpital d'Annecy, Pringy; Philippe Agape, Hôpital Felix Guyon-Centre Hospitalier Universitaire en France (CHU) de la Réunion, La Réunion; Franck E. Nicolini, Centre Hospitalier Lyon Sud, Pierre-Bénite; Bruno Varet, Hôpital Necker, Assistance Publique-Hopitaux de Paris (AP-HP) et Université Paris Descartes; Delphine Réa and Jean Michel Cayuela, Hôpital Saint-Louis, AP-HP, Paris; Martine Gardembas, CHU d'Angers, Angers; Gabriel Etienne and Josy Reiffers, Institut Bergonié; François-Xavier Mahon, Hôpital Haut-Levèque et Université Bordeaux Ségalen, Bordeaux; Lydia Roy, Joëlle Guilhot, and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM) Centres d'Investigation Clinique CHU de Poitiers, Poitiers; Martine Escoffre-Barbe, Centre Hospitalier Pontchaillou, Rennes; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Michel Tulliez, Hôpital Henri Mondor, AP-HP, Créteil; Stéphane Prost, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses; Marc Spentchian, Hôpital Mignot, Le Chesnay; and Jean Claude Chomel and Ali Turhan, INSERM U935, Université Poitiers et Paris Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5797DOI Listing
February 2014

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.

Cancer 2011 Mar 13;117(5):992-1000. Epub 2010 Oct 13.

Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25545DOI Listing
March 2011